Developed countries consume significantly more input - intensive meat and dairy
products than developing countries but as developing countries industrialise, their consumption of these products will increase, putting further pressure on resources.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new
products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European
countries that may increase the amount of discount required on Gilead's
products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger
than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to
develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new
product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current
products, including Biktarvy; Gilead's ability to successfully commercialize its
products, including Biktarvy; the risk that physicians and patients may not see advantages of these
products over other therapies and may therefore be reluctant to prescribe the
products; Gilead's ability to successfully
develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's
product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
More
than 80 per cent of the retailer's
products are designed and
developed in Japan, South Korea, Singapore, Malaysia and China,
countries known for innovation.
Data collected from more
than 13,000 consumers in 21
countries forms the basis of an insight - driven new webinar from DuPont Nutrition & Health, designed to help manufacturers
develop and market sports nutrition and weight management
products.
DuPont Nutrition & Health has collected data from more
than 14,000 consumers in 22
countries for an insight - driven research project designed to help manufacturers
develop and market
products in the health and wellness area.
Last century, formula manufacturers advertised their
products as being better
than breast milk — which proved lethal in some
developing countries where the water used to make up formula is sometimes contaminated.
The 1980s African debt crisis was created by a variety of factors (much more complex
than the commonly attributed «poor African leadership» theory), including irresponsible over-lending by private creditors seeking high returns, the tendency towards one
product commodity economies, the targeting of
developing countries for high interest loans, the global monetary shock of 1979 - 81, trade protectionism in Northern
countries, the depreciation of the US dollar, the prolonged drought of 1981 - 84, among other factors (see African Debt Revisited).
Students and teachers from more
than 120
countries have surfed through these and other Spongelab -
developed products online.
While the average rate of growth has decreased steadily since the 1970s, Moses says the 18 percent of its gross domestic
product (GDP) that the United States spends on health care is 50 to 60 percent higher
than any other
developed country.
Cambridge, MA — A new analysis of the economic impact of effective teachers shows that closing just half of the performance gap with Finland, whose students consistently outperform most
developed countries, could add more
than $ 50 trillion to the U.S. gross domestic
product by 2090.
In
developing countries many of those who grow the
products we consume in the UK earn less
than it costs to run their farm.
Audiobook markets are far more
developed in the US and Europe
than in Japan, with the
products comprising around 10 per cent of book sales in some
countries.
With more
than 9,000 employees, the business markets its
products in more
than 120
countries with operations in
developed and emerging markets and provides comprehensive animal health solutions to veterinarians and the livestock farmers and companion animal owners they support.
Elanco is a global, innovation - driven company that
develops and markets
products to improve animal health production in more
than 75
countries.
Trifexis is made by Elanco, a global, innovation - driven company that
develops and markets
products to improve animal health production in more
than 75
countries.
The audience of industry influencers from more
than 60 different
countries, ready to meet that challenge at the Summit, contained 50 percent travel industry buyers and sellers who actively
develop adventure travel
product and an international pool of media.
While goods and
products are often priced relatively higher due to import duties, services are often quite cheaper
than in the
developed countries.
But China could enhance its national energy security by
developing innovative policies
than prompt change in the
country's energy consumption structure, shifting it from heavy dependence on coal and oil to energy - saving
products and alternative energy.
The U.S. would give
Developing Countries (e.g., Southeast Asia other
than China) special trade incentives (shoot, let's even immediately eliminate bans on exporting U.S. natural gas to just these
Developing Countries)-- for
products (like clothing) that have a verifiable Carbon and Air Quality Standard.
73 As stated in paragraph 37 above, the MAX HAVELAAR label describes
products of fair trade origin purchased at a price and under conditions more favourable
than those determined by market forces from organisations made up of small - scale producers in
developing countries.
Many analysts say the U.S. is a low - tax
country, mostly on the idea that taxes paid as a percentage of gross domestic
product are lower
than most other
developed economies.